Abstract
Real-world analysis of cardiac, gastrointestinal, and hematologic toxicities between commonly used antiemetics in everyday oncology clinical practice.
Author
person
Kavitha Beedupalli
Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center, Shreveport, LA
info_outline
Kavitha Beedupalli, Anil Ananthaneni, Dawood Findakly
Full text
Authors
person
Kavitha Beedupalli
Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center, Shreveport, LA
info_outline
Kavitha Beedupalli, Anil Ananthaneni, Dawood Findakly
Organizations
Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center, Shreveport, LA, LSU Health Shreveport, Shreveport, LA
Abstract Disclosures
Research Funding
No funding received
None.
Background:
Antiemetics are highly effective in chemotherapy-induced nausea and vomiting. We utilized Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluate adverse events (AEs) caused by selected antiemetics commonly used in outpatient oncology practice.
Methods:
We analyzed the FAERS database to assess the cardiac, gastrointestinal (GI), and hematologic AEs for metoclopramide, olanzapine, ondansetron, and promethazine from 2013 through 2022. The disproportionality signal was analyzed by calculating Reporting Odds Ratio (ROR) with a 95% confidence interval (CI)—considered significant when the lower limit of 95% CI was > 1.
Results:
A total of 20,302 AEs were identified, out of which 8,135 (40.1%) were cardiac—arrhythmia and QTc prolongation; 8,656 (42.5%) were GI—nausea/vomiting, constipation/diarrhea, abdominal pain/discomfort, and dyspepsia; and 3,511 (17.3%) were hematologic—leukopenia, thrombocytopenia, anemia, and pancytopenia. Compared to other antiemetics, promethazine and olanzapine had higher cardiac and hematologic AEs, respectively, whereas metoclopramide, followed by ondansetron had higher GI AEs (Table).
Conclusions:
Antiemetics are readily available and effective, yet the preference for a particular drug or drug combination varies. Our study highlights selected antiemetics AEs in order to help individualize treatment for this often challenging and frequently encountered entity.
Metoclopramide
Olanzapine
Ondansetron
Promethazine
Cardiac
-Arrhythmia
-QTc Prolongation
-
554 (5.7%)
307 (3.2%)
-
2,593 (6.5%)
1,179 (2.9%)
-
1,672 (13.8%)
778 (6.4%)
-
883 (26.6%)
169 (5.1%)
Total Cardiac AEs, no. (%)
ROR (95% CI)
861 (8.9%)
0.27 (0.25-0.30)
3,772 (9.4%)
0.43 (0.41-0.46)
2,450 (20.2%)
0.32 (0.30-0.34)
1,052 (31.7%)
1.65 (1.49-1.84)*
GI
-Nausea, and Vomiting
-Constipation, and Diarrhea
-
977 (10.1%)
546 (5.7%)
-
1,383 (3.5%)
1,091 (2.7%)
-
1,446 (11.9%)
1,001 (8.3%)
-
216 (6.5%)
108 (3.2%)
-Abdominal Pain, Discomfort, and Dyspepsia
274 (2.8%)
549 (1.4%)
926 (7.6%)
139 (4.2%)
Total GI AEs, no. (%)
ROR (95% CI)
1,797 (18.6%)
2.22 (2.05-2.40)*
3,023 (7.6%)
0.65 (0.53-0.59)
3,373 (27.8%)
1.56 (1.47-1.65)*
463 (13.9%)
0.52 (0.47-0.59)
Hematologic
-Leukopenia
-Thrombocytopenia
-Anemia
-Pancytopenia
-
74 (0.8%)
124 (1.3%)
118 (1.2%)
52 (0.5%)
-
893 (2.2%)
482 (1.2%)
401 (1.0%)
151 (0.4%)
-
210 (1.7%)
387 (3.2%)
403 (3.3%)
134 (1.1%)
-
10 (0.3%)
30 (0.9%)
29 (0.9%)
13 (0.4%)
Total Hematologic AEs, no. (%)
ROR (95% CI)
368 (3.8%)
0.62 (0.55-0.70)
1,927 (4.8%)
1.75 (1.66-1.93)*
1,134 (9.3%)
0.95 (0.88-1.02)
82 (2.5%)
0.24 (0.19-0.03)
Overall Reported AEs
9,625
39,939
12,110
3,319
* Asterisk in the table denotes a positive signal.
3 organizations
4 drugs
8 targets
Organization
Louisiana State University in ShreveportOrganization
Feist-Weiller Cancer Center at LSUHSC-ShreveportOrganization
LSU Health ShreveportDrug
MetoclopramideDrug
OlanzapineDrug
OndansetronDrug
PromethazineTarget
Histamine receptorsTarget
Muscarinic receptorsTarget
Serotonin receptorsTarget
Histamine H1 receptorTarget
Dopamine receptorsTarget
Adrenergic receptorsTarget
MetoclopramideTarget
5-HT3 receptor